Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

This research study is led by Dr. John McCann.

Contact: Dawn DeMarinis, 413-794-4362

Participation details:

IRB Number: BH16-022

Condition/Disease: Cancer, Cancer - Lung

Location:
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA

Eligibility:
Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria:

• No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer
• No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration; no secondary primary lung cancer diagnosed concurrently or within 2 year prior to registration
• No patients known to be pregnant or lactating

Status: Recruiting

Current Trial Type: Interventional (Clinical Trial), Non-Randomized

Phase: 3